IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
01 11월 2023 - 9:00PM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced William Ho, CEO and co-founder, will
participate in 1x1 meetings at the Truist Securities BioPharma
Symposium being held Wednesday, November 8 and Thursday, November
9, 2023, in New York, NY.
The company expects multiple preclinical and
clinical data updates through year-end 2023 including at the
upcoming Society for Immunology of Cancer (SITC – abstract # 637,
418), Society for Neuro-Oncology (SNO), and American Society of
Hematology (ASH) Annual Meetings.
About IN8bioIN8bio is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of gamma-delta T cell product
candidates for solid and liquid tumors. Gamma-delta T cells are a
specialized population of T cells that possess unique properties,
including the ability to differentiate between healthy and diseased
tissue. IN8bio’s DeltEx platform employs allogeneic, autologous,
iPSC and genetically modified approaches to develop cell therapies,
designed to effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400 in glioblastoma
(GBM) at multiple centers across the United States and has two
ongoing Phase 1 trials in solid and hematological tumors, including
INB-200 for GBM and INB-100 for leukemia patients undergoing
transplantation.
IN8bio also has a broad portfolio of preclinical programs
focused on addressing other hematological and solid tumor cancers.
For more information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio,
Inc.Patrick McCall+ 1 646.600.6GDT (6438)info@IN8bio.com
Investors & Media
Contact:Argot PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024